ABSTRACT
BACKGROUND: Mobility limitation is a component of frailty that shares a bidirectional relationship with cardiovascular disease (CVD). Data are limited on the role of established CVD prevention therapies, such as aspirin, for prevention of frailty and mobility limitation. OBJECTIVES: Examine the association between long-term aspirin use and walking speed. DESIGN, SETTING, PARTICIPANTS: Prospective cohort of 14,315 men who participated in the Physicians' Health Study I, a completed randomized controlled trial of aspirin (1982-1988), with extended post-trial follow-up. MEASUREMENTS: Annual questionnaires collected data on aspirin use, lifestyle and other factors. Average annual aspirin use was categorized for each participant: ≤60 days/year and >60 days/year. Mobility was defined according to self-reported walking pace, categorized as: don't walk regularly (reference), easy/casual <2mph, normal ≥2-2.9mph, or brisk/very brisk ≥3mph. Propensity scoring balanced covariates between aspirin categories. Multinomial logistic regression models estimated odds of being in each self-reported walking category. RESULTS: Mean age was 70±8 years; mean aspirin use 11 years. There were 2,056 (14.3%) participants who reported aspirin use ≤60 days/year. Aspirin use >60 days/year was associated with drinking alcohol, smoking, hypertension, heart disease and stroke, while ≤60 days/year was associated with anticoagulation use and bleeding history. In all, 13% reported not walking regularly, 12% walked <2 mph, 44% walked ≥2-2.9 mph, and 31% walked ≥3 mph. After propensity score adjustment, regular aspirin use was associated with a faster walking speed. Odds ratios (95% confidence intervals) were 1.16 (0.97 to 1.39), 1.24 (1.08 to 1.43), and 1.40 (1.21 to 1.63) for <2 mph, ≥2-2.9 mph and ≥3 mph, respectively, compared to not walking regularly (p-trend<0.001). CONCLUSIONS: In this cohort of older men, long-term aspirin use is associated with a greater probability of faster walking speed later in life.
Subject(s)
Physicians , Walking Speed , Aged , Aspirin , Humans , Male , Prospective Studies , Self ReportABSTRACT
Among elderly participants from the Cardiovascular Health Study, we found that non-esterified trans fatty acid levels had a significant prospective association with hip fracture risk. Other non-esterified fatty acid classes were not associated with hip fracture risk. INTRODUCTION: Serum non-esterified fatty acids (NEFAs) are bioactive metabolic intermediates that can be taken up by bone tissue. Their associations with hip fracture risk have not been previously examined. METHODS: Thirty-five individual NEFAs in five classes (saturated [SFA], mono-un-saturated [MUFA], poly-unsaturated n-6 and n-3 [PUFA], and trans-FA) were measured in Cardiovascular Health Study participants (n = 2139, mean age 77.8 years) without known diabetes. The multivariable associations of NEFA levels with hip fracture risk were evaluated in Cox hazards models. RESULTS: We documented 303 incident hip fractures during 11.1 years of follow-up. Among the five NEFA classes, total trans FA levels were positively associated with higher hip fracture risk (HR 1.17 [95% CI, 1.04, 1.31; p = 0.01] per one standard deviation higher level). The SFA lignoceric acid (24:0) was positively associated with higher risk (HR 1.09 [1.04, 1.1]; p < 0.001), while behenic (22:0) and docosatetraenoic (22:4 n6) acids were associated with lower risk (HR 0.76 [0.61, 0.94]; p = 0.01; 0.84 [0.70, 1.00]; p = 0.05, respectively). CONCLUSION: Total plasma trans NEFA levels are related to hip fracture risk, suggesting an unrecognized benefit of their systematic removal from food. Novel associations of individual NEFAs with hip fracture risk require confirmation in other cohort studies.
Subject(s)
Fatty Acids, Omega-3 , Hip Fractures , Aged , Cohort Studies , Fatty Acids, Nonesterified , Hip Fractures/epidemiology , Hip Fractures/etiology , Humans , Risk FactorsABSTRACT
AIM: Determine whether plasma omega-7 vaccenic acid and palmitoleic acid levels are related to homeostasis model of insulin resistance scores and incident type II diabetes, and whether race/ethnicity modifies these associations. METHODS: Plasma phospholipid fatty acids were measured by gas chromatography with flame-ionization detection in Multi-Ethnic Study of Atherosclerosis participants. Linear regression determined associations of vaccenic acid and palmitoleic acid with log-transformed homeostasis model of insulin resistance scores (n=5689), and Cox regression determined associations with incident type II diabetes (n=5413, 660 cases). Race-interactions were tested. RESULTS: Adjusting for typical risk factors, higher levels of plasma vaccenic acid were found to be inversely associated with insulin resistance scores across all four race/ethnicities, and a significant race-interaction was observed between Hispanics and Caucasians (P for interaction=0.03). Vaccenic acid was related to 17%, 32%, and 39% lower risks of incident type II diabetes in Black, Hispanic, and Chinese American participants, respectively. Differences in associations between races were detected (P for interactions<0.05). By contrast, higher levels of plasma palmitoleic acid were related to greater insulin resistance scores in Blacks (P<0.001) and Hispanics (P<0.001); significant race-based differences between associations were detected (P for interactions<0.05). Palmitoleic acid was correspondingly related to a 21% greater risk of incident type II diabetes in Black individuals. CONCLUSIONS: Results suggest that plasma vaccenic acid and palmitoleic acid are markers of metabolic health and dysfunction, respectively. Coupled with previous evidence and the significant race-interactions, our findings have implications for future studies of the race-based differences in omega-7 fatty acids and their regulation in the context of deteriorating metabolic health.
Subject(s)
Diabetes Mellitus, Type 2/blood , Fatty Acids, Monounsaturated/blood , Metabolic Syndrome/blood , Oleic Acids/blood , Black or African American , Aged , Asian , Biomarkers/blood , Diabetes Mellitus, Type 2/epidemiology , Diabetes Mellitus, Type 2/metabolism , Female , Hispanic or Latino , Humans , Incidence , Insulin Resistance , Linear Models , Male , Metabolic Syndrome/epidemiology , Metabolic Syndrome/metabolism , Middle Aged , Proportional Hazards Models , White PeopleABSTRACT
AIMS: Higher levels of brain natriuretic peptide (BNP) have been associated with a decreased risk of diabetes in adults, but whether BNP is related to insulin resistance in older adults has not been established. METHODS: N-terminal of the pro hormone brain natriuretic peptide (NT-pro BNP) was measured among Cardiovascular Health Study participants at the 1989-1990, 1992-1993 and 1996-1997 examinations. We calculated measures of insulin resistance [homeostatic model assessment of insulin resistance (HOMA-IR), quantitative insulin sensitivity check index (QUICKI), Gutt index, Matsuda index] from fasting and 2-h concentrations of glucose and insulin among 3318 individuals with at least one measure of NT-proBNP and free of heart failure, coronary heart disease and chronic kidney disease, and not taking diabetes medication. We used generalized estimating equations to assess the cross-sectional association of NT-proBNP with measures of insulin resistance. Instrumental variable analysis with an allele score derived from nine genetic variants (single nucleotide polymorphisms) within or near the NPPA and NPPB loci was used to estimate an un-confounded association of NT-proBNP levels on insulin resistance. RESULTS: Lower NT-proBNP levels were associated with higher insulin resistance even after adjustment for BMI, waist circumference and other risk factors (P < 0.001 for all four indices). Although the genetic score was strongly related to measured NT-proBNP levels amongst European Americans (F statistic = 71.08), we observed no association of genetically determined NT-proBNP with insulin resistance (P = 0.38; P = 0.01 for comparison with the association of measured levels of NT-proBNP). CONCLUSIONS: In older adults, lower NT-proBNP is associated with higher insulin resistance, even after adjustment for traditional risk factors. Because related genetic variants were not associated with insulin resistance, the causal nature of this association will require future study.
Subject(s)
Blood Glucose/metabolism , Insulin Resistance/genetics , Insulin/metabolism , Natriuretic Peptide, Brain/metabolism , Peptide Fragments/metabolism , Black or African American/genetics , Aged , Aged, 80 and over , Atrial Natriuretic Factor/genetics , Cross-Sectional Studies , Fasting , Female , Glucose Tolerance Test , Humans , Male , Natriuretic Peptide, Brain/genetics , Polymorphism, Single Nucleotide , White People/geneticsABSTRACT
BACKGROUND AND AIMS: Understanding contributions of lean and fat tissue to cardiovascular and non-cardiovascular mortality may help clarify areas of prevention in older adults. We aimed to define distributions of lean and fat tissue in older adults and their contributions to cause-specific mortality. METHODS AND RESULTS: A total of 1335 participants of the Cardiovascular Health Study (CHS) who underwent dual-energy x-ray absorptiometry (DEXA) scans were included. We used principal components analysis (PCA) to define two independent sources of variation in DEXA-derived body composition, corresponding to principal components composed of lean ("lean PC") and fat ("fat PC") tissue. We used Cox proportional hazards regression using these PCs to investigate the relationship between body composition with cardiovascular and non-cardiovascular mortality. Mean age was 76.2 ± 4.8 years (56% women) with mean body mass index 27.1 ± 4.4 kg/m2. A greater lean PC was associated with lower all-cause (HR = 0.91, 95% CI 0.84-0.98, P = 0.01) and cardiovascular mortality (HR = 0.84, 95% CI 0.74-0.95, P = 0.005). The lowest quartile of the fat PC (least adiposity) was associated with a greater hazard of all-cause mortality (HR = 1.24, 95% CI 1.04-1.48, P = 0.02) relative to fat PCs between the 25th-75th percentile, but the highest quartile did not have a significantly greater hazard (P = 0.70). CONCLUSION: Greater lean tissue mass is associated with improved cardiovascular and overall mortality in the elderly. The lowest levels of fat tissue mass are linked with adverse prognosis, but the highest levels show no significant mortality protection. Prevention efforts in the elderly frail may be best targeted toward improvements in lean muscle mass.
Subject(s)
Body Composition , Cardiovascular Diseases/mortality , Sarcopenia/mortality , Absorptiometry, Photon , Adiposity , Age Factors , Aged , Aged, 80 and over , Body Mass Index , Cardiovascular Diseases/physiopathology , Cardiovascular Diseases/prevention & control , Cause of Death , Comorbidity , Female , Geriatric Assessment , Humans , Male , Multivariate Analysis , Prevalence , Principal Component Analysis , Prognosis , Proportional Hazards Models , Prospective Studies , Protective Factors , Risk Assessment , Risk Factors , Sarcopenia/physiopathology , Sarcopenia/therapy , United States/epidemiologyABSTRACT
UNLABELLED: We examined whether blood levels of two markers of fibrosis (transforming growth factor beta one (TGF-ß1) and procollagen type III N-terminal propeptide (PIIINP)) are related to hip fracture risk and to bone mineral density (BMD). TGF-ß1 levels were associated with lower hip fracture risk in women and with lower BMD in men. PIIINP levels were not associated with either outcome. INTRODUCTION: TGF-ß1 serves several roles in bone formation and resorption. A consequence of TGF-ß1 activation is the production of PIIINP, a marker of collagen III deposition. Here, we explore whether these two biomarkers are related to incident hip fracture and bone mineral density (BMD) and whether their associations are modified by systemic inflammation, as measured by C-reactive protein (CRP) levels. METHODS: Participants were from the Cardiovascular Health Study (mean age 78 years; mean follow-up 8.3 years). We included 1681 persons with measured levels of TGF-ß1 (149 hip fractures) and 3226 persons with measured levels of PIIINP (310 hip fractures). RESULTS: Among women, higher TGF-ß1 levels were associated with lower hip fracture risk (HR, per doubling, 0.78 [95 % CI 0.61, 0.91]). Among men, TGF-ß1 levels were associated with hip fracture risk in a non-linear manner, but among those with elevated CRP levels, doubling was associated with increased risk of fracture (HR 2.22 [1.20, 4.08]) (p = 0.02, interaction between low and high CRP and TGF-ß1 on fracture risk). TGF-ß1 levels had no significant association with total hip or total body BMD in women but were significantly associated with lower BMD in men. There were no associations of PIIINP levels with hip fracture risk or BMD in men or women. CONCLUSIONS: TGF-ß1 levels appear to be associated with bone-related phenotypes in a sex-specific manner. The reasons for these differences between men and women regarding TGF-ß1 levels and hip fracture risk and bone density require further investigation.
Subject(s)
Bone Density/physiology , Hip Fractures/blood , Osteoporotic Fractures/blood , Peptide Fragments/blood , Procollagen/blood , Transforming Growth Factor beta/blood , Absorptiometry, Photon/methods , Aged , Aged, 80 and over , Biomarkers/blood , C-Reactive Protein/metabolism , Female , Fibrosis , Follow-Up Studies , Hip Fractures/physiopathology , Humans , Male , Osteoporotic Fractures/physiopathology , Prospective Studies , Risk Factors , Sex FactorsABSTRACT
OBJECTIVE: Low-density lipoprotein-related receptor protein 1 (LRP1) is a multi-functional endocytic receptor and signaling molecule that is expressed in adipose and the hypothalamus. Evidence for a role of LRP1 in adiposity is accumulating from animal and in vitro models, but data from human studies are limited. The study objectives were to evaluate (i) relationships between LRP1 genotype and anthropometric traits, and (ii) whether these relationships were modified by dietary fatty acids. DESIGN AND METHODS: We conducted race/ethnic-specific meta-analyses using data from 14 studies of US and European whites and 4 of African Americans to evaluate associations of dietary fatty acids and LRP1 genotypes with body mass index (BMI), waist circumference and hip circumference, as well as interactions between dietary fatty acids and LRP1 genotypes. Seven single-nucleotide polymorphisms (SNPs) of LRP1 were evaluated in whites (N up to 42 000) and twelve SNPs in African Americans (N up to 5800). RESULTS: After adjustment for age, sex and population substructure if relevant, for each one unit greater intake of percentage of energy from saturated fat (SFA), BMI was 0.104 kg m(-2) greater, waist was 0.305 cm larger and hip was 0.168 cm larger (all P<0.0001). Other fatty acids were not associated with outcomes. The association of SFA with outcomes varied by genotype at rs2306692 (genotyped in four studies of whites), where the magnitude of the association of SFA intake with each outcome was greater per additional copy of the T allele: 0.107 kg m(-2) greater for BMI (interaction P=0.0001), 0.267 cm for waist (interaction P=0.001) and 0.21 cm for hip (interaction P=0.001). No other significant interactions were observed. CONCLUSION: Dietary SFA and LRP1 genotype may interactively influence anthropometric traits. Further exploration of this, and other diet x genotype interactions, may improve understanding of interindividual variability in the relationships of dietary factors with anthropometric traits.
Subject(s)
Black People , Fatty Acids/metabolism , Low Density Lipoprotein Receptor-Related Protein-1 , Obesity/genetics , Polymorphism, Single Nucleotide , White People , Adipose Tissue , Adult , Aged , Aged, 80 and over , Black People/genetics , Body Mass Index , Europe/epidemiology , Female , Gene Frequency , Gene-Environment Interaction , Genetic Predisposition to Disease , Genotype , Humans , Low Density Lipoprotein Receptor-Related Protein-1/genetics , Low Density Lipoprotein Receptor-Related Protein-1/metabolism , Male , Middle Aged , Obesity/epidemiology , Phenotype , Prevalence , United States/epidemiology , White People/geneticsABSTRACT
AIMS/HYPOTHESIS: We sought to derive and validate a cardiovascular disease (CVD) prediction algorithm for older adults with diabetes, and evaluate the incremental benefit of adding novel circulating biomarkers and measures of subclinical atherosclerosis. METHODS: As part of the Cardiovascular Health Study (CHS), a population-based cohort of adults aged ≥65 years, we examined the 10 year risk of myocardial infarction, stroke and cardiovascular death in 782 older adults with diabetes, in whom 265 events occurred. We validated predictive models in 843 adults with diabetes, who were followed for 7 years in a second cohort, the Multi-Ethnic Study of Atherosclerosis (MESA); here 71 events occurred. RESULTS: The best fitting standard model included age, smoking, systolic blood pressure, total and HDL-cholesterol, creatinine and the use of glucose-lowering agents; however, this model had a C statistic of 0.64 and poorly classified risk in men. Novel biomarkers did not improve discrimination or classification. The addition of ankle-brachial index, electrocardiographic left ventricular hypertrophy and internal carotid intima-media thickness modestly improved discrimination (C statistic 0.68; p = 0.002) and classification (net reclassification improvement [NRI] 0.12; p = 0.01), mainly in those remaining free of CVD. Results were qualitatively similar in the MESA, with a change in C statistic from 0.65 to 0.68 and an NRI of 0.09 upon inclusion of subclinical disease measures. CONCLUSIONS/INTERPRETATION: Standard clinical risk factors and novel biomarkers poorly discriminate and classify CVD risk in older adults with diabetes. The inclusion of subclinical atherosclerotic measures modestly improves these features, but to develop more robust risk prediction, a better understanding of the pathophysiology and determinants of CVD in this patient group is needed.
Subject(s)
Cardiovascular Diseases/classification , Cardiovascular Diseases/epidemiology , Diabetes Mellitus/epidemiology , Aged , Aged, 80 and over , Atherosclerosis/blood , Atherosclerosis/epidemiology , Biomarkers/blood , Blood Pressure/physiology , Cardiovascular Diseases/blood , Carotid Intima-Media Thickness , Cholesterol, HDL/blood , Diabetes Mellitus/blood , Diabetes Mellitus/physiopathology , Female , Humans , Male , Myocardial Infarction/blood , Myocardial Infarction/epidemiology , Regression Analysis , Risk Factors , Stroke/blood , Stroke/epidemiologyABSTRACT
BACKGROUND AND AIMS: While clinical trials have reported beneficial effects of diet, exercise, and weight loss on incident diabetes in subjects with obesity or impaired glucose tolerance, little is known about the incremental benefit of not smoking and moderate drinking on diabetes risk. We sought to examine the association between modifiable lifestyle factors and residual lifetime risk of diabetes. METHODS AND RESULTS: Prospective cohorts involving 20,915 men (1982-2008) and 36,594 women (1992-2008). Modifiable lifestyle factors and adiposity were ascertained at baseline in each cohort and incident diabetes was ascertained during follow up. The mean age at baseline was 53.5 y in men and 54.6 y in women. During an average follow up of 22.6 y in men and 13.0 y in women, 2096 men and 2390 women developed diabetes. At age 45 y, the residual lifetime risk of diabetes (95% CI) for men with 0, 1, 2, 3, and 4 + healthy lifestyle factors was 30.5 (27.3-33.7); 21.5 (19.9-23.0); 15.1 (13.9-16.3); 10.3 (9.1-11.5); and 7.3 (5.7-8.9) percent; respectively. Corresponding values for women were 31.4 (28.3-34.5); 24.1 (21.8-26.5); 14.2 (12.7-15.7); 11.6 (9.7-13.5); and 6.4 (4.2-8.6) percent, respectively. CONCLUSIONS: These data show an inverse and graded relation between desirable lifestyle factors and residual lifetime risk of diabetes in men and women. Not smoking and moderate drinking may have additional benefits when added to exercise, weight control, and diet.
Subject(s)
Diabetes Mellitus/prevention & control , Risk Reduction Behavior , Alcohol Drinking , Body Weight , Cohort Studies , Diabetes Mellitus, Type 2/epidemiology , Diabetes Mellitus, Type 2/prevention & control , Diet , Exercise , Female , Health Behavior , Humans , Life Style , Male , Middle Aged , Physicians , Prospective Studies , Randomized Controlled Trials as Topic , Risk Factors , Smoking Cessation , Women's HealthABSTRACT
BACKGROUND/OBJECTIVES: To provide a reliable assessment of the hypothesized association of fish consumption with stroke risk accumulatively, an updated meta-analysis of published prospective cohort studies was conducted. SUBJECTS/METHODS: Prospective cohort studies through April 2012 in peer-reviewed journals indexed in MEDLINE and EMBASE were selected. Additional information was retrieved through Google or a search of the reference list in relevant articles. The main outcome measure was the weighted hazards ratio (HR) and corresponding 95% confidence interval (CI) for incident stroke according to fish consumption using a random-effects model. RESULTS: A database was derived from 16 eligible studies (19 cohorts), including 402,127 individuals (10,568 incident cases) with an average 12.8 years of follow-up. Compared with those who never consumed fish or ate fish <1/month, the pooled adjusted HRs of total stroke risk were 0.97 (95% CI, 0.87-1.08), 0.86 (0.80-0.93), 0.91 (0.85-0.98) and 0.87 (0.79-0.96) for those who consumed fish 1-3/month, 1/week, 2-4/week and ~5/week, respectively (P(linear trend) = 0.09; P(nonlinear trend) = 0.02). Study location was a modifier. An inverse association between fish intake and stroke incidence was only found by studies conducted in North America. The modest inverse associations were more pronounced with ischemic stroke and were attenuated with hemorrhagic stroke. CONCLUSIONS: Accumulated evidence generated from this meta-analysis suggests that fish intake may have a protective effect against the risk of stroke, particularly ischemic stroke.
Subject(s)
Brain Ischemia/complications , Diet , Fishes , Intracranial Hemorrhages/complications , Seafood , Stroke/prevention & control , Animals , Humans , Risk , Stroke/epidemiology , Stroke/etiologyABSTRACT
AIMS/HYPOTHESIS: Hyperglycaemia disproportionately affects African-Americans (AfAs). We tested the transferability of 18 single-nucleotide polymorphisms (SNPs) associated with glycaemic traits identified in European ancestry (EuA) populations in 5,984 non-diabetic AfAs. METHODS: We meta-analysed SNP associations with fasting glucose (FG) or insulin (FI) in AfAs from five cohorts in the Candidate Gene Association Resource. We: (1) calculated allele frequency differences, variations in linkage disequilibrium (LD), fixation indices (F(st)s) and integrated haplotype scores (iHSs); (2) tested EuA SNPs in AfAs; and (3) interrogated within ± 250 kb around each EuA SNP in AfAs. RESULTS: Allele frequency differences ranged from 0.6% to 54%. F(st) exceeded 0.15 at 6/16 loci, indicating modest population differentiation. All iHSs were <2, suggesting no recent positive selection. For 18 SNPs, all directions of effect were the same and 95% CIs of association overlapped when comparing EuA with AfA. For 17 of 18 loci, at least one SNP was nominally associated with FG in AfAs. Four loci were significantly associated with FG (GCK, p = 5.8 × 10(-8); MTNR1B, p = 8.5 × 10(-9); and FADS1, p = 2.2 × 10(-4)) or FI (GCKR, p = 5.9 × 10(-4)). At GCK and MTNR1B the EuA and AfA SNPs represented the same signal, while at FADS1, and GCKR, the EuA and best AfA SNPs were weakly correlated (r(2) <0.2), suggesting allelic heterogeneity for association with FG at these loci. CONCLUSIONS/INTERPRETATION: Few glycaemic SNPs showed strict evidence of transferability from EuA to AfAs. Four loci were significantly associated in both AfAs and those with EuA after accounting for varying LD across ancestral groups, with new signals emerging to aid fine-mapping.
Subject(s)
Blood Glucose/genetics , Diabetes Mellitus, Type 2/ethnology , Diabetes Mellitus, Type 2/genetics , Hyperglycemia/ethnology , Hyperglycemia/genetics , Insulin/genetics , Adult , Black or African American/genetics , Black or African American/statistics & numerical data , Aged , Aged, 80 and over , Databases, Genetic/statistics & numerical data , Delta-5 Fatty Acid Desaturase , Female , Gene Frequency , Genetic Predisposition to Disease/ethnology , Genetic Predisposition to Disease/genetics , Humans , Linkage Disequilibrium , Male , Middle Aged , Polymorphism, Single Nucleotide/genetics , Quantitative Trait Loci/genetics , Risk Factors , White People/genetics , White People/statistics & numerical data , Young AdultABSTRACT
BACKGROUND: Atrial Fibrillation is highly prevalent in clinical practice affecting approximately 2.3 million people in USA and 4.5 million people in European Union. The aim of the study was to examine the association between nut consumption and incident atrial fibrillation. METHODS: Prospective cohort of 21,054 male participants of Physicians' Health Study I. Nut consumption was estimated using food frequency questionnaire and incident atrial fibrillation was ascertained through yearly follow-up questionnaires. Cox regression was used to estimate relative risks of atrial fibrillation. RESULTS: The average age was 54.6 ± 9.5 years (40.7-87.1). During a mean follow up of 20 years (median 24 years), 3,317 cases of atrial fibrillation occurred. The crude incidence rate was 7.6, 7.4, 8.2, 7.9, and 6.8 cases/1000 person-years for people reporting nut consumption of rarely/never, 1-3/month, 1/per week, 2-6/week, and ≥ 7/week, respectively. Multivariable adjusted hazard ratios (95% CI) for incident atrial fibrillation were 1.00 (ref), 1.00 (0.90-1.11), 1.09 (0.97-1.21), 1.07 (0.95-1.21), and 0.91 (0.70-1.17) for nut consumption from the lowest to the highest category of nut consumption (p for trend 0.26). No statistically significant association between nut consumption and atrial fibrillation was found when stratified by body mass index (BMI < 25 vs ≥ 25 kg/m2) or age (< 65 vs. ≥ 65 years). CONCLUSIONS: Our data did not show an association between nut consumption and incident atrial fibrillation among US male physicians.
Subject(s)
Atrial Fibrillation/epidemiology , Health Status , Nuts , Physicians/statistics & numerical data , Adult , Aged , Aged, 80 and over , Atrial Fibrillation/etiology , Atrial Fibrillation/prevention & control , Body Mass Index , Diet , Follow-Up Studies , Humans , Incidence , Male , Middle Aged , Multivariate Analysis , Odds Ratio , Proportional Hazards Models , Prospective Studies , Randomized Controlled Trials as Topic , Risk Factors , Surveys and QuestionnairesABSTRACT
Cocoa products, which are rich sources of flavonoids, have been shown to reduce blood pressure and the risk of cardiovascular disease. Dark chocolate contains saturated fat and is a source of dietary calories; consequently, it is important to determine whether consumption of dark chocolate adversely affects the blood lipid profile. The objective was to examine the effects of dark chocolate/cocoa product consumption on the lipid profile using published trials. A detailed literature search was conducted via MEDLINE (from 1966 to May 2010), CENTRAL and ClinicalTrials.gov for randomized controlled clinical trials assessing the effects of flavanol-rich cocoa products or dark chocolate on lipid profile. The primary effect measure was the difference in means of the final measurements between the intervention and control groups. In all, 10 clinical trials consisting of 320 participants were included in the analysis. Treatment duration ranged from 2 to 12 weeks. Intervention with dark chocolate/cocoa products significantly reduced serum low-density lipoprotein (LDL) and total cholesterol (TC) levels (differences in means (95% CI) were -5.90 mg/dl (-10.47, -1.32 mg/dl) and -6.23 mg/dl (-11.60, -0.85 mg/dl), respectively). No statistically significant effects were observed for high-density lipoprotein (HDL) (difference in means (95% CI): -0.76 mg/dl (-3.02 to 1.51 mg/dl)) and triglyceride (TG) (-5.06 mg/dl (-13.45 to 3.32 mg/dl)). These data are consistent with beneficial effects of dark chocolate/cocoa products on total and LDL cholesterol and no major effects on HDL and TG in short-term intervention trials.
Subject(s)
Cacao/chemistry , Flavonoids/pharmacology , Lipoproteins, HDL/drug effects , Lipoproteins, LDL/drug effects , Blood Pressure/drug effects , Cardiovascular Diseases/drug therapy , Databases, Factual , Humans , Lipoproteins, HDL/blood , Lipoproteins, LDL/blood , Randomized Controlled Trials as Topic , Triglycerides/bloodABSTRACT
BACKGROUND AND AIMS: Heart failure (HF) remains a major public health issue. Red meat and dietary heme iron have been associated with an increased risk of coronary heart disease and hypertension, two major risk factors for HF. However, it is not known whether red meat intake influences the risk of HF. We therefore examined the association between red meat consumption and incident HF. METHODS AND RESULTS: We prospectively studied 21,120 apparently healthy men (mean age 54.6 y) from the Physicians' Health Study (1982-2008). Red meat was assessed by an abbreviated food questionnaire and incident HF was ascertained through annual follow-up questionnaires. We used Cox proportional hazard models to estimate hazard ratios. In a multivariable model, there was a positive and graded relation between red meat consumption and HF [hazard ratio (95% CI) of 1.0 (reference), 1.02 (0.85-1.22), 1.08 (0.90-1.30), 1.17 (0.97-1.41), and 1.24 (1.03-1.48) from the lowest to the highest quintile of red meat, respectively (p for trend 0.007)]. This association was observed for HF with (p for trend 0.035) and without (p for trend 0.038) antecedent myocardial infarction. CONCLUSION: Our data suggest that higher intake of red meat is associated with an increased risk of HF.
Subject(s)
Heart Failure/etiology , Meat/adverse effects , Physicians , Aged , Cholesterol, Dietary/adverse effects , Dietary Fats/adverse effects , Double-Blind Method , Follow-Up Studies , Health Surveys , Heart Failure/epidemiology , Heme/administration & dosage , Humans , Incidence , Iron, Dietary/adverse effects , Male , Middle Aged , Myocardial Infarction/epidemiology , Myocardial Infarction/physiopathology , Proportional Hazards Models , Risk Factors , Surveys and Questionnaires , United States/epidemiologyABSTRACT
Given the higher burden of risk factors for metabolic syndrome (MetS) on morbidity and mortality, it is critical to prevent the development of metabolic syndrome in the first place. While dietary habits have been favorably associated with some of the factors included in the definition of metabolic syndrome, limited and inconsistent data have been reported on the role of nutrition in the development of metabolic syndrome. Currently, there is no consensus as to which dietary patterns would confer the lowest risk of MetS. Identification of dietary patterns, food groups, or nutrients that may lower the incidence of metabolic syndrome could improve prevention strategies as well as prognosis among subjects with existing MetS. This manuscript reviews current evidence on dietary patterns, consumption of fat, whole grains, carbohydrate quality and quantity, and moderate alcohol consumption as they relate to metabolic syndrome.
Subject(s)
Diet , Metabolic Syndrome/prevention & control , Alcohol Drinking , Cardiovascular Diseases/complications , Diet/trends , Edible Grain , Fats , Humans , Obesity/complications , Obesity/prevention & control , Risk FactorsABSTRACT
BACKGROUND/OBJECTIVES: While type II diabetes (DM) is a major cause of morbidity in the United States, limited data are available on the association between nut intake and incident DM. We sought to examine the association between nut consumption and the risk of DM. SUBJECTS/METHODS: Prospective cohort of 20 224 male participants of the Physicians' Health Study I. Nut consumption was estimated using a 19-item brief food frequency questionnaire, and incident DM was ascertained through yearly follow-up questionnaires. Cox regression was used to estimate relative risks of DM. RESULTS: The average age of the study participants was 54.4+/-9.4 years (range: 40.7-87.1). During a mean follow-up of 19.2 years, 1828 cases of DM occurred. The crude incidence rates of DM were 4.82, 4.85, 4.92, 4.16, 4.29 and 3.32 cases per 1000 person-years for individuals reporting nut consumption of rarely/never, <1, 1, 2-4, 5-6 and 7+ servings per week, respectively. While nut consumption was associated with a lower risk of DM in a model adjusted for age (P for tend 0.017), such relation was attenuated on additional control for other confounders (multivariable adjusted hazard ratios (95% confidence interval) for DM were 1.0 (reference), 1.06 (0.93-1.20), 1.10 (0.95-1.26), 0.97 (0.82-1.14), 0.99 (0.76-1.30) and 0.87 (0.61-1.24) from the lowest to the highest category of nut consumption, respectively (P for trend 0.99). No statistically significant association between nut consumption and DM was found in either lean or overweight/obese participants. CONCLUSIONS: Our data do not show an association between nut consumption and incident DM in US male physicians.
Subject(s)
Diabetes Mellitus, Type 2/epidemiology , Diet , Nuts , Diabetes Mellitus, Type 2/prevention & control , Diet Surveys , Humans , Incidence , Male , Middle Aged , Models, Biological , Proportional Hazards Models , Risk Factors , Surveys and QuestionnairesABSTRACT
BACKGROUND: Although heart failure (HF) remains a major public health issue, limited data are available on the utility of parental information on the risk of HF in offspring. MATERIALS AND METHODS: We prospectively examined the association between parental history of myocardial infarction (MI) and incident HF among 20,187 offspring in the Physicians' Health Study I. Parental history and age at MI was assessed by a questionnaire and a Cox regression was used to estimate relative risks of HF. RESULTS: After an average follow-up of 19.6 years, 1036 new HF cases were documented. Overall, while a history of early parental MI (before age 55) was associated with a 32% increased risk of HF in offspring compared with subjects whose parent did not have MI, parental MI at older ages was not associated with HF risk. However, the relation between parental history of MI and HF was stronger and mainly observed for HF with antecedent MI. Compared with subjects without parental history of MI, multivariable adjusted hazard ratios (95% CI) for HF with antecedent MI were 3.44 (2.15-5.51), 2.24 (1.20-4.21), 1.26 (0.63-2.51), and 1.37 (0.92-2.03) for parental MI occurred at the age of < 55, 55-59, 60-64, and 65 + y, respectively. CONCLUSIONS: Our data suggest that parental MI at an early age is a strong and independent predictor of HF with antecedent MI among US male physicians. This information, along with existing tools, may help clinicians identify patients at risk of HF with antecedent MI.
Subject(s)
Family Health , Heart Failure/genetics , Myocardial Infarction/genetics , Physicians , Adult , Age Factors , Aged , Aged, 80 and over , Epidemiologic Methods , Heart Failure/epidemiology , Humans , Male , Middle Aged , Myocardial Infarction/epidemiology , Pedigree , Risk Factors , Stroke Volume/physiology , United States/epidemiologyABSTRACT
AIMS/HYPOTHESIS: The heritability of fasting serum insulin and glucose concentrations in non-diabetic members of multiplex hypertensive families is unknown. METHODS: We calculated the familial aggregation of fasting serum glucose and insulin concentrations and performed a genome-wide scan to assess whether quantitative trait loci contribute to these phenotypes in 2,412 non-diabetic individuals from 1,030 families enrolled in the Hypertension Genetic Epidemiology Network (HyperGEN) in the Family Blood Pressure Program. RESULTS: The heritability (+/-SE) of fasting serum insulin was 0.47+/-0.085 in European Americans and 0.28+/-0.08 in African Americans (p<0.0001 for both), after adjusting for age, sex, and BMI. A genome-wide scan for fasting serum insulin yielded a maximum log of the odds (LOD) score of 2.36 on chromosome 5 at 20 cM (p=0.0004) in European Americans, and an LOD score of 2.28 on chromosome 19 at 11 cM (p=0.0004) in African Americans. The heritability of fasting serum glucose was 0.5109+/-0.08 in the former and 0.29+/-0.09 in the latter (p<0.0003 for both) after adjusting for age, sex and BMI. A genome-wide scan for fasting serum glucose revealed a maximum LOD score of 2.07 on chromosome 5 at 26 cM (p=0.0009) in European Americans. CONCLUSIONS/INTERPRETATION: These analyses demonstrate the marked heritability of fasting serum insulin and glucose concentrations in families enriched for the presence of members with hypertension. They suggest that genes associated with fasting serum insulin concentration are present on chromosomes 19 and 5, and that genes associated with fasting serum glucose concentration are on chromosome 5, in families enriched for hypertension.
Subject(s)
Blood Glucose/metabolism , Genome, Human , Hypertension/genetics , Insulin/blood , Quantitative Trait Loci/genetics , Adult , Black or African American/genetics , Aged , Analysis of Variance , Chromosomes, Human, Pair 19/genetics , Chromosomes, Human, Pair 5/genetics , Family Health , Fasting , Female , Genetic Linkage/genetics , Genotype , Humans , Hypertension/blood , Insulin Resistance/genetics , Male , Markov Chains , Middle Aged , Pedigree , Phenotype , Quantitative Trait, Heritable , United States , White People/geneticsABSTRACT
Huntington disease (HD) is a neurodegenerative disorder caused by the abnormal expansion of CAG repeats in the HD gene on chromosome 4p16.3. Past studies have shown that the size of expanded CAG repeat is inversely associated with age at onset (AO) of HD. It is not known whether the normal Huntington allele size influences the relation between the expanded repeat and AO of HD. Data collected from two independent cohorts were used to test the hypothesis that the unexpanded CAG repeat interacts with the expanded CAG repeat to influence AO of HD. In the New England Huntington Disease Center Without Walls (NEHD) cohort of 221 HD affected persons and in the HD-MAPS cohort of 533 HD affected persons, we found evidence supporting an interaction between the expanded and unexpanded CAG repeat sizes which influences AO of HD (P = 0.08 and 0.07, respectively). The association was statistically significant when both cohorts were combined (P = 0.012). The estimated heritability of the AO residual was 0.56 after adjustment for normal and expanded repeats and their interaction. An analysis of tertiles of repeats sizes revealed that the effect of the normal allele is seen among persons with large HD repeat sizes (47-83). These findings suggest that an increase in the size of the normal repeat may mitigate the expression of the disease among HD affected persons with large expanded CAG repeats.
Subject(s)
Huntington Disease/genetics , Trinucleotide Repeats , Adolescent , Adult , Age of Onset , Aged , Aged, 80 and over , Child , Child, Preschool , Cohort Studies , Humans , Middle Aged , New England , Probability , Survival RateABSTRACT
BACKGROUND: Huntington's disease (HD) is an autosomal dominant disease with neurologic manifestations. In transgenic mouse models of HD, weight loss is recognized as a feature associated with the disease onset. It is unclear whether a similar pattern occurs in humans. METHODS: Data from the Huntington Study Group were used to evaluate whether HD is associated with lower body mass index (BMI) at the earliest stage of the disease. There were 361 case subjects in whom HD had been diagnosed with an independence scale rating of 100 (no special care needed), a total functional capacity score of >or=11, and HD duration of <4 years. For each case subject, five sex- and age-matched control subjects were selected from the National Heart, Lung, and Blood Institute Family Heart Study or the Framingham Offspring Study. RESULTS: Among case subjects, neither disease duration, nor dystonia, nor chorea score was significantly associated with BMI. BMI was significantly lower among case than among control subjects. Among men, age-adjusted BMI (+/-SE) was 25.90 +/- 0.34 kg/m(2) for case subjects with HD and 27.68 +/- 0.16 kg/m(2) for control subjects. Among women, corresponding values were 24.34 +/- 0.43 for case subjects with HD and 26.63 +/- 0.21 kg/m(2) for control subjects. CONCLUSIONS: At an early stage of the disease, subjects with Huntington's disease had lower body mass index than matched controls from the general population. The cause of weight loss is unknown but the parallel to observations in Huntington's disease transgenic mice suggests that it is a significant hallmark of Huntington's disease gene expression.